HK Stock Movement | INNOGEN-B (02591) Rises Over 6% Again After Surging 30% Yesterday, Included in Hang Seng Composite Index

Stock News11-25

INNOGEN-B (02591) climbed more than 6% again, following a surge of over 30% in the previous session. At the time of writing, the stock was up 6.11% to HK$40.3, with a turnover of HK$23.13 million.

The rally comes after the company was included in the Hang Seng Composite Index following the quarterly review results announced on November 21. The changes will take effect from December 8, 2025.

Earlier, Shanghai Securities highlighted INNOGEN-B's promising drug candidate, Esupaglutide α, which demonstrates strong safety and efficacy in lowering blood sugar and weight loss. The drug shows significant potential in treating chronic metabolic diseases such as diabetes, obesity, and fatty liver. The company's listing on the Hong Kong Exchange is expected to accelerate its R&D pipeline and commercialization efforts.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1188100270?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-25 11:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188100270","market":"other","top_or_hot":-1,"title":"HK Stock Movement | INNOGEN-B (02591) Rises Over 6% Again After Surging 30% Yesterday, Included in Hang Seng Composite Index","media":"Stock News","content":"<p>INNOGEN-B (02591) climbed more than 6% again, following a surge of over 30% in the previous session. At the time of writing, the stock was up 6.11% to HK$40.3, with a turnover of HK$23.13 million.</p>\n<p>The rally comes after the company was included in the Hang Seng Composite Index following the quarterly review results announced on November 21. The changes will take effect from December 8, 2025.</p>\n<p>Earlier, Shanghai Securities highlighted INNOGEN-B's promising drug candidate, Esupaglutide α, which demonstrates strong safety and efficacy in lowering blood sugar and weight loss. The drug shows significant potential in treating chronic metabolic diseases such as diabetes, obesity, and fatty liver. The company's listing on the Hong Kong Exchange is expected to accelerate its R&D pipeline and commercialization efforts.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | INNOGEN-B (02591) Rises Over 6% Again After Surging 30% Yesterday, Included in Hang Seng Composite Index</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | INNOGEN-B (02591) Rises Over 6% Again After Surging 30% Yesterday, Included in Hang Seng Composite Index\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-25 11:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>INNOGEN-B (02591) climbed more than 6% again, following a surge of over 30% in the previous session. At the time of writing, the stock was up 6.11% to HK$40.3, with a turnover of HK$23.13 million.</p>\n<p>The rally comes after the company was included in the Hang Seng Composite Index following the quarterly review results announced on November 21. The changes will take effect from December 8, 2025.</p>\n<p>Earlier, Shanghai Securities highlighted INNOGEN-B's promising drug candidate, Esupaglutide α, which demonstrates strong safety and efficacy in lowering blood sugar and weight loss. The drug shows significant potential in treating chronic metabolic diseases such as diabetes, obesity, and fatty liver. The company's listing on the Hong Kong Exchange is expected to accelerate its R&D pipeline and commercialization efforts.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02591","symbol_name":"银诺医药－Ｂ","start_time":0,"source_url":"","article_id":"1188100270","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188100270","pubTimestamp":1764041657,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"INNOGEN-B (02591) climbed more than 6% again, following a surge of over 30% in the previous session. At the time of writing, the stock was up 6.11% to HK$40.3, with a turnover of HK$23.13 million....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02591":"银诺医药－Ｂ","BK1161":"生物科技"},"translate_title":"港股动向|英诺健-B(02591)继昨日急升30%后再升逾6%纳入恒生综合指数","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02591":1},"content_text":"INNOGEN-B (02591) climbed more than 6% again, following a surge of over 30% in the previous session. At the time of writing, the stock was up 6.11% to HK$40.3, with a turnover of HK$23.13 million.\nThe rally comes after the company was included in the Hang Seng Composite Index following the quarterly review results announced on November 21. The changes will take effect from December 8, 2025.\nEarlier, Shanghai Securities highlighted INNOGEN-B's promising drug candidate, Esupaglutide α, which demonstrates strong safety and efficacy in lowering blood sugar and weight loss. The drug shows significant potential in treating chronic metabolic diseases such as diabetes, obesity, and fatty liver. The company's listing on the Hong Kong Exchange is expected to accelerate its R&D pipeline and commercialization efforts.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1188100270","isCrawlerRequest":true}